Boston Scientific Corp (BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Ticker
BSX
Exchange
NYSE
Sector
Healthcare
Industry
Medical Devices
Market cap
$63.22B
52-week range
$39.57 - $101.91

Valuation

Share price
$43.64 (close of Nov 18, 2026)
P/E (TTM)
18.41x
Price to book
2.44x
Price to free cash flow
18.98x
Enterprise value
$74.57B
Book value per share
$17.86

Price performance

PeriodChange
1 day+1.42%
5 days-3.30%
1 month-1.69%
3 months-13.53%
6 months-21.96%
Year to date-54.23%
1 year-56.02%
3 years-19.69%
5 years+5.90%
10 years+104.50%
All time+919.33%

Short interest

As of
Oct 30, 2026
Short % of float
2.43%
Shares short
35.11M
Days to cover
1.65
Change since prior report
-13.74%
Source
FINRA consolidated short interest

Members of Congress who disclosed BSX trades

Gilbert Ray Cisneros · Kevin Hern · Lisa McClain · John Boozman · Bruce Westerman · Val Hoyle · Alan Armstrong · Jefferson Shreve · Markwayne Mullin

Super investors holding BSX

Dodge & Cox (Dodge & Cox Funds) · Ken Griffin (Citadel) · First Pacific Advisors (First Pacific Advisors, LP) · Sarah Ketterer (Causeway Capital Management LLC) · Ray Dalio (Bridgewater Associates) · Mairs & Power (Mairs & Power Inc) · Lee Ainslie (Maverick Capital LTD)

Profitability and growth

Return on equity
11.82%
Return on invested capital
8.69%
Return on assets
6.62%
Return on capital employed
9.45%
Gross margin
69.01%
Net margin
14.41%
EBITDA margin
24.81%
Revenue growth
19.87%
Net income growth
56.66%
Free cash flow growth
38.30%

Cash flow and balance sheet

Free cash flow yield (TTM)
5.27%
Current ratio
1.36x
Net debt to EBITDA
2.08x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$20.07B
Cost of revenue
$6.22B
Gross profit
$13.85B
EBITDA
$4.98B
Net income
$2.89B
Earnings per share
$1.96
Research and development
$2.05B
Interest expense
$349.00M
Shares outstanding
1.48B

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$20.07B$13.85B$2.89B$1.96
2024-12-31$16.75B$11.49B$1.85B$1.26
2023-12-31$14.24B$9.90B$1.59B$1.08
2022-12-31$12.68B$8.73B$698.00M$0.45
2021-12-31$11.89B$8.18B$1.04B$0.69
2020-12-31$9.91B$6.45B-$82.00M-$0.08
2019-12-31$10.73B$7.62B$4.70B$3.38
2018-12-31$9.82B$7.01B$1.67B$1.21
2017-12-31$9.05B$6.46B$104.00M$0.08
2016-12-31$8.39B$5.96B$347.00M$0.26

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3169.01%14.41%11.82%8.69%
2024-12-3168.61%11.02%8.39%6.62%
2023-12-3169.49%11.18%8.15%6.72%
2022-12-3168.81%5.50%3.97%4.49%
2021-12-3168.78%8.76%6.26%4.45%
2020-12-3165.05%-0.83%-0.54%-0.32%
2019-12-3170.98%43.78%33.87%6.27%
2018-12-3171.37%17.01%19.15%9.54%
2017-12-3171.34%1.15%1.48%5.09%
2016-12-3171.09%4.14%5.15%3.66%

Cash and debt by year

Period endCashDebt
2025-12-31$1.97B$11.14B
2024-12-31$414.00M$8.97B
2023-12-31$865.00M$8.57B
2022-12-31$928.00M$8.91B
2021-12-31$1.93B$8.80B
2020-12-31$1.73B$9.13B
2019-12-31$217.00M$8.59B
2018-12-31$146.00M$4.80B
2017-12-31$188.00M$3.81B
2016-12-31$196.00M$5.42B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$3.66B$299.00M
2024-12-31$2.65B$266.00M
2023-12-31$1.79B$233.00M
2022-12-31$938.00M$220.00M
2021-12-31$1.32B$194.00M
2020-12-31$1.13B$170.00M
2019-12-31$1.38B$157.00M
2018-12-31-$6.00M$140.00M
2017-12-31$1.11B$127.00M
2016-12-31$806.00M$116.00M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-28Sep 2026$0.73
2026-07-29Jun 2026$0.83
2026-04-22Mar 2026$0.80
2026-02-04Dec 2025$0.78
2025-10-22Sep 2025$0.71
2025-07-23Jun 2025$0.72
2025-04-23Mar 2025$0.67
2025-02-05Dec 2024$0.65

Filings and sources

Company website
bostonscientific.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Edwards Lifesciences Corp (EW) · Stryker Corp (SYK) · GE HealthCare Technologies Inc. (GEHC) · Medtronic plc (MDT) · Dexcom Inc (DXCM) · Abbott Laboratories (ABT) · STERIS plc (STE) · Zimmer Biomet Holdings, Inc. (ZBH)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades